Chemical biology and experimental therapeutics

Leader of the research programme:

Associate Professor Marián Hajdúch, MD., PhD.
Petr Džubák, MD., PhD.

Research program provides high throughput (HTS) screening on a broad diversity of assays and detection platforms. A comprehensive
program is responsible for all operational stages in the lead generation pipeline - assay development, modification
and validation, optimization of chemical structure of potent and selective hit compounds identified by HTS, and
interactive chemistry to optimize a drug development lead. Our HTS platform is designed as an industry strength, highly
flexible modular HTS and uHTS. It is one of the largest academic installation of HTS and HCA technologies, including screening
in BSL3 and BSL2+ environments, in combination with ionizing irradiation (screening of DNA damage/repair interfering
compounds), mass spectrometry based screening, etc. The platform enables screening of entire or cherry-picked parts of our
compound bank as well as the screening of collaborator’s compounds and libraries.

Deliverables: 1. Assay methods: Validated HTS screening protocols for individual biological activities; 2. Selection of Hits: List of hits selected from the primary screen using a threshold based on statistical criteria; 3. Validated hits resynthesized or repurchased and retested; 4. Clinical drug candidates. Deliverables will be published in the form of papers, research reports, patents and conference presentations.

Key methodological approaches: High throughput screening of biological activities, genomics, proteomics, metabolomics, bioanalytics, in vivo analysis of biological activities of compounds